Antimicrobials Stewardship by Pharmacist

Infection Clinical Trial

Official title:

Appropriate Use of Controlled Broad-spectrum Antimicrobials by Establish Stewardship and Execute by Antibiotic Pharmacist

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02768454
• Other study ID #: 201511065RIND
• Status: Active, not recruiting
• Phase: N/A
• First received: February 11, 2016
• Last updated: May 11, 2016
• Start date: September 2015
• Est. completion date: September 2016

Study information

• Verified date: May 2016
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

To study the outcome of antibiotics stewardship

Description:

Retrospective cohort study by medical review and evaluation of broad-spectrum antibiotics to determine how appropriately it was bing used.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 99 Years

Eligibility

inclusion criteria:

• Inpatient with infectious disease and under broad-spectrum antibiotics

exclusion criteria:

• Poor prognosis was diagnosed or received conservative therapy only.

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Infection

Intervention

Drug:
• medical review of controlled broad-spectrum antibiotics
medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Yun-Lin	Dou-Liou

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of appropriateness of empirical antibiotics choosing.	For example,the inappropriate of piperacillin-tazobactam as empirical therapy was numbers of participants with no risk factors of deep tissue infection or DM foot /Number of participants treated with piperacillin-tazobactam for soft tissue infection.	up to 8 weeks	No
Primary	The percentage of appropriateness of de-escalation of therapy.	For example,continued piperacillin-tazobactam was seen to be inappropriate when microbiologic results and clinical status permit de-escalation.	up to 8 weeks	No
Secondary	Number of adverse events of antibiotics were recorded.		up to 8 weeks	Yes